1Serneri GG, Boddi M, Cecioni I, et al. Cardiac angiotensin Ⅱformation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res, 2001, 88(9): 961-968.
2Schultz, JE, Witt SA, Glascock BJ, et al. TGF- β mediates the hypertrophic cardiomyocyte growth induced by angiotensin Ⅱ. J Clin Invest, 2002, 109 (6): 787-796.
3Lorell BH. Role of angiotensin AT1 and AT2 receptors in cardiac hypertrophy and disease. Am J Cardiol, 1999, 83(12A): 48-52.
4Akishita M, Yamada H, Dzau VJ, et al. Increased vasoconstrictor response of the mouse lacking angiotensin Ⅱ type 2 receptor.Biochem Biophys Res Commun, 1999, 261(2): 345-349.
5Brogelli L, Parenti A, Ledda F. Inhibition of vascular smooth muscle cell growth by angiotensin type 2 receptor stimulation for in vitro organ culture model. J Cardiovasc Pharmacol, 2002, 39(5) :739-745.
6Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomized trail against atenold. Lancet, 2002, 359(9311): 995～1003.
7Dickstein K. ELITE Ⅱ and Val- HeFT are different trials: together what do they tell us? Curr Control Trials Cardiovasc Med,2001, 2 (5): 240-243.
8Pitt B, Poole- Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- - the Losartan Heart Failure Survival Study ELITE Ⅱ. Lancet, 2000, 355 (9215) :1582～1587.
9Lee S, Kramer CM, Mankad S, et al. Combined angiotensin converting enzyme inhibition and angiotensin AT1 receptor blockade up- regulates myocardial AT2 receptors in remodeled myocardium post - infarction. Cardiovasc Res, 2001, 51(1):131～139.
2[1]Brunner HP,Rocca MD,Vaddadi G,et al. Recent insight into therapy of congestive heart failure: focus on ACE inhibition and angiotensin-Ⅱ antagono ism[J].J Am CollCardiol,1999,33(5):1163-1173.
3[2]Cleland JG,Morgan K. Inhibition of the renin-angiotension-aldosterone system in heart failure:new insights from basic clinical research[J]. Curr Opin Cardiol, 1996,11: 252-262.
4[3]Struthers AD. Angiotensin Ⅱ receptor antagonists for heart failure[J].Heart,1998,80:5-6.
5[4]Liu YH,Yang XP,Sharov VG,et al. Effects of angiotension-converting enzyme inhibitors and angiotensin Ⅱ type Ⅰ receptor antagonists in rats with heart failure. Role of kins and angiotensin Ⅱ type Ⅱ receptors[J]. J Clin In vest, 1997,99(8): 1926-1935.
6[5]Ruzicka M, Baoxue Y,Frans HH,et al. Effects of enalapril versus Iosartan on regression of volume overload induced cardiac hypertrophy in rats[J]. Circu lation , 1994,90( 1 ): 484-491.
7[6]Schieffer B,Wirger A,Meybrunn M,et al. Comparative effects of chronic an giotension-converting enzyme inhibitors and angiotensin Ⅱ type I receptoe blockade on cardiac remodeling after myocardial infarction in the rat[ J ]. Cir culation, 1994,89(5): 2273-2282.
8[7]Kim S,Zhan Y,Izumi Y,et al. Cardiovascular effects of combination of perindopril,candesartan,and amlodipine in hypertensive rats[J ]. Hyperten sion, 2000,35 (3): 769-774.
9[8]Turcani M,Rupp H. Development of pressure overload induced cardiae hy pertrophy is unaffected by long-term treatment with Iosartan[ J ]. Moll Cell Biochem, 1998, 188:225-233.
10[9]Shen YT,Wiedmann RT,Greenland BD,et al. Combined effects of angioten sion converting enzyme inhibitors and angiotensin Ⅱ receptor antagonism in conscious pigs with congestive heart failure [J ]. Cardiovasc Res, 1998, 39(2):413-422.
6Ghanem FA,Movahed A.Should angiotensin receptor blockers be added to angiotensin-converting enzyme inhibitors in the treatment of heart failure?[J].Rev Cardiovasc Med,2005,6(4):206-213.
7Sebillon P,Bouchier C,Bidot LD,et al.Expanding the phenotype of LMNA mutations in dilated cardiomyopathy and functional consequences of these mutations[J].J Med Genet,2003,40(8):560-567.
8Nikolova V,Leimena C,McMahon AC,et al.Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice[J].J Clin Invest,2004,113(3):349-351.
9Schwarz ER,Pollick C,Dow J,et al.A small animal model of non-ischemic cardiomyopathy and its evaluation by transthoracic echocardiography[J].Cardiovasc Res,1998,39(1):216-223.
